Apellis Pharmaceuticals (APLS) Announces Proposed 7M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Apellis Pharmaceuticals (APLS) Prices 9.5M Share Offering at $37/Sh
January 9, 2020 5:55 AM ESTApellis Pharmaceuticals, Inc. (NASDAQ: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting... More
Apellis Pharmaceuticals (APLS) files automatic mixed securities shelf
January 7, 2020 4:05 PM ESTApellis Pharmaceuticals (NASDAQ: APLS) files automatic mixed securities shelf
... MoreApellis Pharmaceuticals (APLS) PT Raised to $62 at Oppenheimer
January 7, 2020 3:26 PM ESTOppenheimer analyst Justin Kim raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $62.00 (from $52.00) while maintaining a Outperform rating.
... MoreApellis Pharmaceuticals (APLS) PT Raised to $80 at Citi
January 7, 2020 2:57 PM ESTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $80.00 (from $37.00) while maintaining a Buy rating.
... MorePre-Open Stock Movers 01/07: (APLS) (TYME) (APA) Higher (CRNC) (ITCI) (ARE) Lower (more...)
January 7, 2020 9:30 AM ESTToday's Pre-Open Stock Movers
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) 36.8% HIGHER; Announced positive results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Top-line data show that pegcetacoplan met the studys primary efficacy endpoint, demonstrating... More
Apellis Pharmaceuticals (APLS) PT Raised to 'Street High' $70 at Baird
January 7, 2020 9:08 AM ESTBaird analyst Brian Skorney raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to a 'Street High' $70.00 (from $45.00) while maintaining a Outperform rating.
... MoreApellis Pharmaceuticals (APLS) Data Exceeded Expectations, Expect Shares to Fly - Cantor Fitzgerald
January 7, 2020 8:08 AM ESTCantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $54.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS) following positive data.
Merle commented, "We think positive Ph3 data well exceeds investor expectations. As we wrote in our preview (link), we think investors... More
Alexion Pharma (ALXN) Shares on Watch After Positive Data from Competitor Apellis Pharmaceuticals (APLS) in PNH
January 7, 2020 7:10 AM ESTAlexion Pharma (NASDAQ: ALXN) Shares on Watch After Positive Data from Competitor Apellis Pharmaceuticals (NASDAQ: APLS) in PNH
... MoreApellis Pharmaceuticals (APLS) to Resume Trading at 7:30 am
January 7, 2020 7:07 AM ESTApellis Pharmaceuticals (NASDAQ: APLS) to Resume Trading at 7:30 am
... MoreApellis Pharmaceuticals (APLS) Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with PNH Met the Primary Efficacy Endpoint
January 7, 2020 7:01 AM ESTApellis... More
Apellis Pharmaceuticals (APLS) Halted, News Pending
January 7, 2020 6:58 AM ESTApellis Pharmaceuticals (NASDAQ: APLS) Halted, News Pending
... MoreSVB Leerink Starts Apellis Pharmaceuticals (APLS) at Market Perform
January 7, 2020 6:12 AM ESTSVB Leerink analyst Dae Gon Ha initiates coverage on Apellis Pharmaceuticals (NASDAQ: APLS) with a Market Perform rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals... More
